Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion
Merck KGaA, Darmstadt, Germany, agreed to acquire Silence Therapeutics for $1.3B. The deal values Silence at $1.1B enterprise value and includes its siRNA therapy divesiran. Merck plans to fund the acquisition with new debt and expects to close the deal in Q1 2027. Silence shareholders will receive $20 per ADS, an 82% premium.
How this was made
The 30-second read
Why it matters
The acquisition expands Merck KGaA's specialty‑medicine portfolio and may accelerate development of RNA‑based treatments, while signaling confidence in the siRNA market.
Market read
A major cross‑border M&A deal in the biotech space, likely to influence sector valuations and investor sentiment toward RNA therapeutics.
What to watch
Potential competition from other RNA‑based therapies and the need for additional financing could strain Merck KGaA's balance sheet.
Background
Merck KGaA announced a definitive agreement to acquire Silence Therapeutics for $1.3 billion in cash, aiming to add the siRNA asset divesiran to its rare‑disease pipeline.
Market effects
The deal highlights increased consolidation in the siRNA biotech sector, potentially boosting valuations of peer companies developing RNA therapeutics.
European pharma M&A activity may see heightened interest as Merck KGaA expands its pipeline, influencing German and UK market sentiment.
Large‑cap European pharma acquisition could affect global biotech funding flows and investor appetite for similar cross‑border deals.
Counterpoint
If integration challenges or regulatory hurdles delay the transaction, the premium paid may not be justified, weighing on Merck KGaA's stock.
Key entities
- CompanyMerck KGaA
German pharmaceutical and chemicals group acquiring Silence Therapeutics.
- CompanySilence Therapeutics
London‑based biotech developing siRNA therapies, target of the acquisition.
